Dermatologists’ attitude towards psoriasis treatment during the COVID-19 pandemic

Article Details

Authors
Tiago Torres, Marta Pereira, Maria João Paiva Lopes, Clarisse Rebelo, Pedro Andrade, Martinha Henrique, Hugo Oliveira, Paulo Ferreira, Gabriela Marques Pinto, Francisco Menezes Brandão, Jorge Rozeira, Paulo Filipe, Rui Tavares Bello

Article Type
Original Research

DOI
10.7573/dic.2021-4-4

Related Articles

Article Page

Abstract

Background: The COVID-19 pandemic introduced new challenges in several dimensions in healthcare services. Herein, we describe the real-life strategies and therapeutic options adopted by dermatologists regarding their patients with psoriasis being treated with or with an indication for systemic therapy during the first COVID-19 lockdown period in Portugal.

Methods: The study involves a web-based survey on the clinical management of systemic therapy for psoriasis during the COVID-19 pandemic administered to Portuguese dermatologists. The survey consisted of 55 questions (4 openended questions; 51 closed-ended questions), grouped into 6 sections.

Results: A total of 60 dermatologists voluntarily participated in this survey. Nearly 63% of the participants opted for suspending biologics during the COVID-19 lockdown period and 23.3% increased the time between drug administrations. Eighty percent of the participants agreed that biologics did not change the probability of acquiring COVID-19 and 58.4% believed that these drugs decreased or did not change the severity of the disease. Approximately one-third of the participants opted not to prescribe a biological agent in patients despite clinical indication over the duration of the pandemic. Nearly 25% of the participants opted for suspending traditional immunosuppressant administration. Virtual appointments were an option for 93.3% of the participants.

Conclusion: The COVID-19 pandemic has significantly affected the management of patients with psoriasis being treated with or with an indication for systemic therapy. Some of the decisions made during the first lockdown period were contrary to what we know today. These decisions might have had a significant impact on patients’ quality of life and on future therapeutic success. An adequate interpretation and analysis of the available data will be extremely important to an insightful adaptation of the clinical practice in future confinement or restrictive scenarios.

Keywords: biological agents, COVID-19, dermatology, immunosuppression, psoriasis.

Citation: Torres T, Pereira M, Paiva Lopes MJ, Rebelo C, Pedro Andrade P, Henrique M, Oliveira H, Ferreira P, Marques Pinto G, Menezes Brandão F, Rozeira J, Filipe P, Tavares Bello R. Dermatologists’ attitude during the COVID-19 pandemic. Drugs in Context 2021; 10: 2021-4-4. DOI: 10.7573/dic.2021-4-4

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: TT has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Boehringer Ingelheim, Biogen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, Fresenius Kabi, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, Sanofi and UCB. MP has received honoraria for acting as a consultant and/or as a speaker from Janssen and LEO Pharma. MJPL has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Janssen, LEO Pharma, Novartis, Pfizer and Octapharma. MH has received honoraria for acting as a consultant and/or as a speaker from Novartis. HO has received honoraria for acting as a consultant and/or as a speaker from LEO Pharma and Novartis. PFe has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Eli Lilly, Janssen, LEO Pharma, Novartis and Pfizer. GMP has received honoraria for acting as a consultant and/or as a speaker from AbbVie, Almirall, Lilly, Janssen, LEO Pharma, Novartis and Pfizer. FMB has received honoraria for acting as a consultant and/or as a speaker from Janssen. RTB has received honoraria for acting as a consultant and/or as a speaker from Abbvie, Bioderma, Galderma, Janssen, LEO Pharma, Eli Lilly, Medinfar, Novartis, Pfizer and UCB. JR, CR, PA and PFi have no conflicts of interest to declare. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/05/dic.2021-4-4-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Torres T, Pereira M, Paiva Lopes MJ, Rebelo C, Pedro Andrade P, Henrique M, Oliveira H, Ferreira P, Marques Pinto G, Menezes Brandão F, Rozeira J, Filipe P, Tavares Bello R. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Torres T, Pereira M, Paiva Lopes MJ, Rebelo C, Pedro Andrade P, Henrique M, Oliveira H, Ferreira P, Marques Pinto G, Menezes Brandão F, Rozeira J, Filipe P, Tavares Bello R. https://doi.org/10.7573/dic.2021-4-4. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/dermatologists-attitude-towards-psoriasis-treatment-during-the-covid-19-pandemic

Correspondence: Tiago Torres, Department of Dermatology, Centro Hospitalar do Porto, Rua D Manuel II, S/N, 4050-344, Porto, Portugal. Email: torres.tiago@outlook.com

Provenance: Invited; externally peer reviewed.

Submitted: 24 April 2021; Accepted: 12 May 2021; Publication date: 9 June 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF